Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
about
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinomaThe European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for humCurrent and emerging therapies in unresectable and recurrent gastric cancerTaxanes in the Treatment of Advanced Gastric CancerAdvanced gastric cancer: Current treatment landscape and future perspectivesChemotherapy in Elderly Patients with Gastric CancerCompanion diagnostics for the targeted therapy of gastric cancerClinical utility of ramucirumab in advanced gastric cancerMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyEfficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsPositioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinomaIs conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationSrc mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsHER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerPhase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.A unified model of the hierarchical and stochastic theories of gastric cancer.Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
P2860
Q24186222-2C4BF0D8-C586-45EE-99AD-E5B6F5079D54Q24633301-44BD9A61-3253-45F1-9E94-028F2C281DABQ26745453-43516207-E25A-4B4B-8567-BC6F7596BFA6Q26747708-B6F40560-9591-407C-977E-9AA0FF9A3092Q26764934-35A01D46-E712-4CCE-B37F-67F7A78480A5Q26771424-FF19AEF0-DA0F-4561-8EDA-60973443BE91Q26780298-E32BC853-CE4A-40CB-B4EF-49C2BF447271Q26785665-1A9FBBFF-39B3-473B-974E-0E8F0E397423Q26798420-3A6B3FCE-7E8A-4326-B402-A17AE70AC43EQ26865057-EF1E14DD-74F9-4307-BFE6-EC576F77FCB7Q27028095-682C2E28-00F9-4E4E-8A86-EFFB07BF3FACQ28079750-3886E130-E223-4EE8-98D5-37C31E4141A7Q28084888-B82490FF-EF06-48D5-9786-6B6688E0D75BQ28544422-D6C09030-3360-4E30-8910-E443DFCC796AQ30837184-DF5977AB-98D2-496E-A537-E0EBCB629EBCQ33386875-DD5D7108-0DAC-41AC-BF33-50F134AA4F33Q33387432-7B34F153-7CEF-48BE-84BF-392B5C89C6D3Q33389563-1EEEA83D-4AFC-4832-960E-72EF8E51A794Q33391384-CAB41B51-52EF-42CB-8D5F-D62CADABC42AQ33396506-B158C021-74A7-4921-9063-89D1027FC7DCQ33397356-165B6D87-08D7-4FB9-B983-94447C61538CQ33399530-49C06D70-9C9B-401B-ADF9-2265542212C6Q33407676-A1D416C3-BE35-4CB9-8385-BF73A3E50619Q33408000-254027E7-AB28-428F-85C4-7B7E98AC5F76Q33413350-AF86F7BA-F2FA-4D57-9662-D94D18BAF4AAQ33413548-D609596D-C950-4C7B-922C-AA7E08919267Q33416500-78635051-2099-49AF-8C48-6EEA09817E95Q33420157-CB5755CE-9B92-42FC-9EE3-19993226EE2BQ33421868-D2FBCDD4-10CC-4768-8C59-43E95BDB6815Q33426501-837A518B-BFA1-41F9-98A0-777EA68D1880Q33426732-90EC172A-D710-4C3E-ACA4-B25AE40DC12EQ33429869-2D8564FE-82F2-45F2-8325-89EA6BDFDC93Q33432199-B898D1B6-F888-41A7-87EB-634F943CCC63Q33442681-A94681D7-AF14-4E87-8487-538206980D98Q33574315-A9479969-D9AA-4887-9176-E58DEC12BD61Q33577624-E2F80DE1-05C9-4772-A1A8-85A611C56EFBQ33594906-5BBECC3B-98D1-4AC5-BFF2-52622F2E522CQ33729150-AE4A8616-843E-4C1C-A4BE-5B67B544217AQ33779701-184F5EE5-3C8C-466B-8657-79CA20AAA1B0Q33849656-B2DF0159-050F-4009-8470-3155AB043CBD
P2860
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@ast
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@en
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@nl
type
label
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@ast
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@en
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@nl
prefLabel
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@ast
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@en
Capecitabine/cisplatin versus ...... hase III noninferiority trial.
@nl
P2093
P2860
P356
P1433
P1476
Capecitabine/cisplatin versus ...... phase III noninferiority trial
@en
P2093
J Santamaria
M Lichinitser
M Philco-Salas
P I McCloud
P2860
P304
P356
10.1093/ANNONC/MDN717
P50
P577
2009-01-19T00:00:00Z